Rat IgG2b isotype control-InVivo

目录号：A2116         批次号: A211615

       克隆号：LTF-2

打印

Rat IgG2b isotype control-InVivo 单克隆抗体（克隆号：LTF-2）可与锁孔血蓝蛋白 (keyhole limpet hemocyanin, KLH) 发生反应。由于哺乳动物不表达 KLH，因此该抗体非常适合在大多数体内和体外应用中用作大鼠 IgG2b 抗体的同种型匹配对照。

抗体信息

克隆号 LTF-2
配制 PBS Buffer, PH 7.4
推荐同型对照 Rat IgG2b, κ
来源 CHO
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 7.54 mg/mL
内毒素 ＜1 EU/mg

客户使用selleck产品的实验数据

Rat IgG2b isotype control-InVivo在文献中得到引用

Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity [ Nat Commun, 2025, 16(1):3546] PubMed: 40229277
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma [ Cancer Commun (Lond), 2025, 10.1002/cac2.70036] PubMed: 40443016
BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma [ Cell Rep Med, 2025, 6(3):101995] PubMed: 40107246
USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer [ Pharmacol Res, 2025, S1043-6618(25)00093-3] PubMed: 40020887
Faecalibacterium prausnitzii promotes anti-PD-L1 efficacy in natural killer/T-cell lymphoma by enhancing antitumor immunity [ BMC Med, 2025, 23(1):387] PubMed: 40597177
Myeloid-lineage-specific membrane protein LRRC25 suppresses immunity in solid tumor and is a potential cancer immunotherapy checkpoint target [ Cell Rep, 2025, 44(5):115631] PubMed: 40279244
Tumor microenvironment-associated oxidative stress impairs SIRT1 secretion to suppress anti-tumor immune response [ Cell Rep, 2025, 44(5):115679] PubMed: 40343797
Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis [ Br J Cancer, 2025, 10.1038/s41416-025-03105-2] PubMed: 40715695
Lipin1-dependent transcriptional inactivation of SREBPs contributes to selinexor sensitivity in multiple myeloma [ Acta Pharmacol Sin, 2025, 10.1038/s41401-025-01553-3] PubMed: 40229499
Urokinase-type plasminogen activator deficiency enhances CD8+ T cell infiltration and anti-PD-1 therapy efficacy in prostate cancer [ Front Immunol, 2025, 16:1625226] PubMed: 40959092

禁止用于人体及治疗！